Dexmedetomidine, Ozone and Dexamethasone Local Injection in Carpal Tunnel Syndrome for Pain Relief
A Comparative Study Between Dexmedetomidine, Ozone and Dexamethasone Local Injection in Carpal Tunnel Syndrome for Long- Term Pain Relief
Tanta University
135 participants
Nov 1, 2023
INTERVENTIONAL
Conditions
Summary
The aim of the present study is to compare the analgesic efficacy of Dexmedetomidine, Ozone and Dexamethasone regional injection in carpal tunnel syndrome.
Eligibility
Inclusion Criteria3
- Age from 20 to 60 years.
- Both sexes.
- Patients with ultrasonographic evidence of mild-to-moderate carpal tunnel syndrome (CTS).
Exclusion Criteria14
- Patient refusal.
- Patients with severe symptoms and signs of CTS as identified per the American Association of Neuromuscular and Electro diagnostic Medicine (AANEM) guidelines,\[14\] as this is an indication for surgery,
- Patients who show improvement on medical treatment,
- Previous surgical or injectional CTS treatment,
- Pregnancy ,co existence of brachial plexopathy, or thoracic outlet syndrome, polyneuropathy, radiculopathy and peripheral nerve lesion in upper limb.
- Severe cardiovascular disease
- Morbid obese patients (body mass index (BMI) of \>35 kg/m2)
- Infection at site of injection.
- Bleeding diathesis.
- History of thyroid deficiency, uncontrolled diabetes mellitus , rheumatoid arthritis and history of glucose-6-phosphate dehydrogenase (G6PD) deficiency
- History of Ozone or Dexmedetomidine allergy.
- End stage renal and hepatic disease.
- History of inflammatory joint , connective tissue disorders, , burns, any local tissue contractures and history of wrist trauma.
- Patients who will not consent to completing The visual analogue scale (VAS) for pain or nerve conduction study before and after injection.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Patients will receive injection of 1 microgram/kg dexmedetomidine average (70-100-microgram) (0.7-1ml) plus 4ml lidocaine injection nearby median nerve.
Participants will receive a single local injection of 4 ml ozone (10 micrograms/ml) plus to 1 ml lidocaine (1%) using a 25 G needle.
Patients will receive a single local injection of 5 mL (3 mL lidocaine (1%) and 2 mL \[8 mg\] dexamethasone) via the same technique.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06133712